Outsourced microbiological support to hospital-based surveillance of CDI aims to increase the capacity of laboratories in EU/EEA Member States to perform diagnostic practices with high diagnostic accuracy and acquire comparable typing data from C. difficile isolates.
To improve the understanding of experienced HIV stigma in the community, ECDC initiated an exploratory survey in 2021 to measure HIV-related stigma across Europe and Central Asia.
This evidence brief summarises the progress towards UN Sustainable Development Goal 3.3 to ‘eliminate the epidemic of AIDS’ in Europe and Central Asia.
Progress towards ending the AIDS epidemic by 2030 is variable across the region, and most countries in Europe and Central Asia are currently far from achieving the 2025 targets.
Tuberculosis (TB) is a major cause of morbidity and mortality in Europe. High-quality laboratory diagnosis of TB is the basis for both individual patient treatment and surveillance.
For 2021, the 30 countries in the European Union/European Economic Area (EU/EEA) reported a total of 33 527 tuberculosis (TB) cases (7.4 per 100 000 population).
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis C. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis C.